NICE expands Lucentis use; FDA OKs Alzheimer's detection drug; Pfizer reports spending $2.3M last quarter on lobbying;

@FiercePharma: ICYMI: GSK saves $431M moving retirees to private healthcare exchanges. Story | Follow @FiercePharma

@EricPFierce: South Africa's Aspen Pharmacare is a major generic drugmaker poised to get bigger. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: With Aptalis sale a no-go, TPG plots IPO instead. More | Follow @CarlyHFierce

> The U.K. cost watchdog NICE has approved Novartis' ($NVS) Lucentis for the treatment of choroidal neovascularization (CNV) associated with a form of short-sightedness called pathological myopia. Story

> The FDA has approved a second brain imaging drug that will help in the detection of Alzheimer's disease and dementia. Release

> Ireland's Shire ($SHPG) has upped its earnings projections for two years based on the sales of its popular ADHD drugs. Story

> The European Medicines Agency (EMA) says Novo Nordisk ($NVO) is recalling batches of its NovoMix 30 FlexPen and Penfill insulin prodcuts because some of them may contain improper dosing. Story

> For a second year running, Science magazine has named Regeneron Pharmaceuticals ($REGN) the top employer in the global biopharmaceutical industry. Story

Medical Device News

@FierceMedDev: Myriad slaps Quest with BRCA cancer test patent suit. Article | Follow @FierceMedDev

@MarkHFierce: Stryker paid $13.2M to settle SEC bribery charges, but doesn't admit or deny any wrongdoing. Story | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes & Ladders from FierceBiotech: Eli Lilly's board elects multinational financial leader, and more. Item | Follow @MichaelGFierce

> Med tech VC Versant raising $250M new fund amid sluggish market. More

> Report: ICU Medical pulls the plug on billion-dollar buyout effort. News

> ResMed's respiratory device sales drive more global growth. Story

Biotech News

@FierceBiotech: J&J wins FDA panel blessing for Hepatitis C blockbuster hopeful. Story | Follow @FierceBiotech

@JohnCFierce: Let's see. Friday. Today Gilead's team will take its bows at the sofosbuvir panel. Then a vote and break for celebratory drinks, pictures. | Follow @JohnCFierce

@DamianFierce: Aerie prices $67M IPO and becomes 40th biotech to go public this year. More | Follow @DamianFierce

@EmilyMFierce: When is a medical treatment unnecessary? Article | Follow @EmilyMFierce

> Public Citizen goes on a witch hunt at the FDA. Editor's corner

> Versant Ventures amassing $200M fund for biotech upstarts. More

> Alexion bags another FDA 'breakthrough' for rare-disease drug. Story

And Finally... Pfizer ($PFE) reported spending $2.28 million in the third quarter for lobbying, up $850,000 (55%) from the $1,530,000 it reported spending in the second quarter. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.